Why did SIGHT.PA stock drop after hours on 11 Mar 2026?

The after‑hours drop of **16.15%** to **€0.09** followed heavy volume and growing investor caution ahead of GenSight’s **20 Mar 2026** update; liquidity and binary clinical risks typically amplify selling in small‑cap biotech names.

What is Meyka AI forecasting for SIGHT.PA stock?

Meyka AI's forecast model projects a near‑term level of **€0.08**, implying about **-12.45%** from the current **€0.0914**; forecasts are model‑based projections and not guarantees.

What are realistic price targets for SIGHT.PA stock?

We outline a conservative target of **€0.05** (down **-45.28%**), a base of **€0.08** (model forecast), and an optimistic **€0.20** (up **+118.82%**) if clinical or strategic news is positive.

Is SIGHT.PA stock a buy after this decline?

Views are mixed: Meyka AI grades SIGHT.PA **B+ (BUY)** at score **72.50**, but third‑party ratings show a **C / Sell**. This is a speculative, high‑volatility play requiring careful risk management and research.

EU Stocks

SIGHT.PA GenSight Biologics EURONEXT after hours: down 16.15% to €0.09, catalysts ahead

ByHuzaifa Zahoor March 11, 2026March 11, 2026

SIGHT.PA stock fell sharply in after-hours trading on 11 Mar 2026, dropping 16.15% to €0.09 on volume of 2,727,402 shares. That move pushed GenSight Biologics S.A. (SIGHT.PA) well below its 200‑day average of €0.13 and showed a relative surge in selling versus the 50‑day average volume of 1,740,345. Investors are focused on near-term clinical and cash‑runway catalysts, including the company’s earnings/earnings‑related update scheduled for 20 Mar 2026, which likely amplified after‑hours pressure on EURONEXT Europe trading.